S100A6在急性髓细胞白血病中的表达及对疗效的影响

包红雨; 王建宁; 孟庆齐; 宋敏

doi:10.16766/j.cnki.issn.1674-4152.2017.07.007

S100A6在急性髓细胞白血病中的表达及对疗效的影响

doi: 10.16766/j.cnki.issn.1674-4152.2017.07.007

南京医科大学第二附属医院血液科, 江苏南京 210000

基金项目:

南京医科大学第二附属医院青年科技启动基金项目（QN201001）；南京医科大学科技发展基金重点项目（2012NJMU089）；江苏省“六大人才高峰”第11批次高层人才选拔培养资助项目（WSN-019）

详细信息

通讯作者:
包红雨,E-mail:baohongyu77@163.com

中图分类号: R733.71;R730.43
计量
- 文章访问数: 176
- HTML全文浏览量: 26
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2016-09-18
- 网络出版日期: 2022-08-04

Expression of S100A6 in AML and Its Influence no Curative Effect

Department of Hematology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000, China

摘要

摘要: 目的了解S100A6 mRNA在人急性髓细胞白血病(AML)中的表达及对疗效、预后的影响。方法选取南京医科大学第二附属医院2009年11月—2014年6月收治的初治AML患者42例,另选取健康对照者12例,Real-time PCR检测AML患者治疗前后及对照组骨髓单个核细胞S100A6 mRNA表达,比较AML患者与对照组及AML不同类型间S100A6表达。比较M3、M4、M5患者中治疗有效组与治疗无效组治疗前后S100A6表达差异,复发组与无复发组S100A6表达差异,比较M3、M4、M5患者S100A6高表达组与低表达组间CR1(第一次完全缓解)、CR2(第二次完全缓解)的表达差异、2年总生存率(OS)表达差异及复发率表达差异。采用SPSS 19.0统计软件比较各组间差异。结果 S100A6在M3、M4、M5患者中表达较对照组高(P<0.05),在M1、M2、M6、M7患者中表达较对照组差异无统计学意义(P>0.05)。M3、M4、M5患者治疗有效组治疗前后S100A6表达差异有统计学意义(P<0.05),治疗无效组差异无统计学意义(P>0.05)。M3、M4、M5患者2年内复发组治疗前S100A6表达较无复发组高(P<0.05)。S100A6高表达组与低表达组间CR1率、CR2率、2年OS率差异均无统计学意义(P>0.05)。M3、M4、M5患者S100A6高表达组较低表达组复发率明显提高(P<0.05)。结论 S100A6在AML患者中的表达与AML分型、疗效及预后相关,可作为白血病疾病诊断分子标志之一。
- S100A6 /
- 急性髓细胞白血病 /
- 分型 /
- 疗效
Abstract: Objective To investigate the expression of S100A6 in AML and its influence no curative effect. Methods Collecting 42 AML patients and 12 normal persons, the expression of S100A6 mRNA in these AML patients was determined by real time quantitative PCR (RQ-PCR).The expressions in AML patients and normal persons, different types AML patients, the patients before and after the therapy were compared.The expression differences before and after the therapy between the effective treatment group and the ineffective treatment group of AML-M3, M4, M5 patients were compared.The expression differences before the therapy between the recurrence group within two years and the no recurrence group within two years of AML-M3, M4, M5 patients were compared.The expression differences of CR1, CR2 between the high expression group and the low expression group of AML-M3, M4, M5 patients were compared.The expression differences of OS in two years between the high expression group and the low expression group of AML-M3, M4, M5 patients were compared.The expression differences of relapse between the high expression group and the low expression group of AML-M3, M4, M5 patients were compared.All the results were analyzed by statistic. Results Compared with normal persons, the expression lever of S100A6 in the AML-M3, M4, M5 patients was higher (P < 0.05), the expression lever in the AML-M1, M2, M6, M7 patients was not different (P > 0.05).The expression of S100A6 in the AML-M3, M4, M5 patients who have effective treatment has difference between before and after therapy (P < 0.05), the expression of S100A6 in these patients who have no effective treatment has no difference between before and after therapy (P > 0.05).The expression of S100A6 in the AML-M3, M4, M5 patients who relapsed in two years was higher than that in the patients who have not relapsed in two years (P < 0.05).The rate of CR1 and CR2 in the S100A6 high expression group is no statistical difference with the rate of the low expression group of AML-M3, M4, M5 patients (P > 0.05).The rate of OS in two years in the S100A6 high expression group is no statistical difference with the low expression group of AML-M3, M4, M5 patients (P > 0.05).The rate of relapse in the S100A6 high expression group is higher than that of low expression group of AML-M3, M4, M5 patients (P < 0.05). Conclusion The expression of S100A6 in AML patients is related to the patients' styles, curative effect and prognosis.It might be the diagnosis molecular markers of AML.
- S100A6 /
- AML /
- Style /
- Curative effect